Argos Therapeutics, Inc. (ARGS) To Present At The 2nd Annual Sachs Cancer Bio Partnering & Investment Forum
3/17/2014 9:12:31 AM
DURHAM, N.C., March 17, 2014 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS), a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis™ technology platform, today announced that Doug Plessinger, vice president of clinical and medical affairs, is scheduled to present at the 2nd Annual Sachs Cancer Bio Partnering & Investment Forum at the New York Academy of Sciences in New York City. Mr. Plessinger's presentation will include an update on Argos's clinical development program for AGS-003, the company's personalized immunotherapy currently in a pivotal phase 3 clinical trial for the treatment of metastatic renal cell carcinoma.
Help employers find you! Check out all the jobs and post your resume.
comments powered by